Sun Pharma sharpens R&D for efficiencies with digital applications

Sun Pharma is adopting digital solutions in research and development for efficiencies as pricing pressure continues to hurt US business.

The drug maker has guided for an increase in R&D expenses in FY 19 as it builds a pipeline of specialty products. Expenses will also see an increase this year as it plans three key launches in US, including its psoriasis drug (Ilumya), eye drops (OTX-101) and anti cancer drug (Yonsa). This would require upfront investments to build up a field force and this will put pressure on margins.

“We are building a digital collaborative platform that will help in